| For the past five years, Mitsubishi Tanabe Pharma Canada (MTP-CA) has been committed to supporting Canadians diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their caregivers. In 2018, MTP-CA introduced the first new treatment for ALS in almost 20 years and has been at the forefront of research and innovation to support the ALS community ever since. “[We’re] focused on areas that we believe will have the greatest impact for patients—both within and beyond medicine,” says Andy Zylak, president of MTP-CA. On our site, read about what MTP-CA is doing for the future—and the present—of ALS care. |
